Developmental differences in IFN signaling affect GATA1s-induced megakaryocyte hyperproliferation

Journal of Clinical Investigation

Volumn 123, Issue 8, 2013, Pages 3292-3304

  Woo, Andrew J ^a,d   Wieland, Karen ^a,e   Huang, Hui ^a   Akie, Thomas E ^a   Piers, Taylor ^a   Kim, Jonghwan ^b   Cantor, Alan B ^a,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ALPHA INTERFERON RECEPTOR 1; INTERFERON; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DOWN SYNDROME; GENE EXPRESSION; HEMATOPOIESIS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN VITRO STUDY; MEGAKARYOCYTE; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRANSGENIC MOUSE; UPREGULATION;

EID: 84881256257     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI40609     Document Type: Article

References (45)

1. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down's syndrome: a review. Pediatr Hematol Oncol. 1987;4(3):211-230.
2. Robison LL. Down syndrome and leukemia. Leukemia. 1992;6(Suppl. 1):5-7.
3. Avet-Loiseau H, Mechinaud F, Harousseau JL. Clonal hematologic disorders in Down syndrome. A review. J Pediatr Hematol Oncol. 1995;17(1):19-24.
4. Zipursky A, Brown EJ, Christensen H, Doyle J. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome. Clin Lab Med. 1999;19(1):157-167, vii.
5. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr. 2005; 217(3):126-134.
6. Bourquin JP, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A. 2006;103(9):3339-3344.
7. Ito E, et al. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome. Br J Haematol. 1995;90(3):607-614.
8. Massey GV, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. 2006; 107(12):4606-4613.
9. Klusmann JH, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008;111(6):2991-2998.
10. Wechsler J, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32(1):148-152.
11. Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101(11):4298-4300.
12. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101(11):4301-4304.
13. Ahmed M, et al. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103(7):2480-2489.
14. Groet J, et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet. 2003;361(9369):1617-1620.
15. Rainis L, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102(3):981-986.
16. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;16(13):3965-3973.
17. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93(9):2867-2875.
18. Harigae H, Xu G, Sugawara T, Ishikawa I, Toki T, Ito E. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome. Blood. 2004;103(8):3242-3243.
19. Hollanda LM, et al. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet. 2006;38(7):807-812.
20. Sankaran VG, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012;122(7):2439-2443.
21. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005; 37(6):613-619.
22. Pronk CJ, et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell. 2007; 1(4):428-442.
23. Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood. 2000; 96(6):2093-2099.
24. Kiladjian JJ, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065-3072.
25. Abegg-Werter MJ, Raemaekers JM, de Pauw BE, Haanen C. Recombinant interferon-alpha, but not interferon-gamma is effective therapy for essential thrombocythemia. Blut. 1990;60(1):37-40.
26. Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 2007;18(5-6):459-471.
27. Muller U, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994; 264(5167):1918-1921.
28. Negrotto S, et al. Expression and functionality of type I interferon receptor in the megakaryocytic lineage. J Thromb Haemost. 2011;9(12):2477-2485.
29. Xu J, et al. Combinatorial assembly of developmental stage-specific enhancers controls gene expression programs during human erythropoiesis. Dev Cell. 2012;23(4):796-811.
30. Matsuyama T, et al. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell. 1993;75(1):83-97.
31. Essers MA, et al. IFNα activates dormant haematopoietic stem cells in vivo. Nature. 2009; 458(7240):904-908.
32. Klimmeck D, Hansson J, Raffel S, Vakhrushev SY, Trumpp A, Krijgsveld J. Proteomic cornerstones of hematopoietic stem cell differentiation: distinct signatures of multipotent progenitors and myeloid committed cells. Mol Cell Proteomics. 2012; 11(8):286-302.
33. Nakamura K, Deyama Y, Yoshimura Y, Suzuki K, Morita M. Toll-like receptor 3 ligand-induced antiviral response in mouse osteoblastic cells. Int J Mol Med. 2007;19(5):771-775.
34. Takayanagi H, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature. 2002;416(6882):744-749.
35. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415-1421.
36. Li X, Leung S, Qureshi S, Darnell JE Jr, Stark GR. Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-α. J Biol Chem. 1996; 271(10):5790-5794.
37. Muntean AG, Crispino JD. Differential requirements for the activation domain and FOGinteraction surface of GATA-1 in megakaryocyte gene expression and development. Blood. 2005; 106(4):1223-1231.
38. Huang Z, Richmond TD, Muntean AG, Barber DL, Weiss MJ, Crispino JD. STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice. J Clin Invest. 2007;117(12):3890-3899.
39. Klusmann JH, et al. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Deve. 2010; 24(15):1659-1672.
40. Liu ZJ, Sola-Visner M. Neonatal and adult megakaryopoiesis. Curr Opin Hematol. 2011;18(5):330-337.
41. Silver RT, Vandris K, Goldman JJ. Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011; 117(24):6669-6672.
42. Liu T, et al. Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol. 2011;12(8):R83.
43. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
44. Radaeva S, et al. Interferon-α activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology. 2002; 122(4):1020-1034.
45. Browne EP, Wing B, Coleman D, Shenk T. Altered cellular mRNA levels in human cytomegalovirus- infected fibroblasts: viral block to the accumulation of antiviral mRNAs. J Virol. 2001; 75(24):12319-12330.